BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

BIOA has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup increased their price objective on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioAge Labs presently has an average rating of “Hold” and an average price target of $15.00.

BioAge Labs Trading Up 10.6%

Shares of BIOA opened at $11.61 on Friday. The company’s fifty day moving average price is $7.34. The firm has a market capitalization of $416.22 million, a P/E ratio of -7.64 and a beta of 1.74. BioAge Labs has a 1 year low of $2.88 and a 1 year high of $20.37.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

Insider Buying and Selling

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $10.19, for a total transaction of $702,060.43. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs in the third quarter valued at $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of BioAge Labs in the 2nd quarter worth $27,000. Bank of America Corp DE grew its holdings in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after acquiring an additional 3,517 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of BioAge Labs during the second quarter valued at $57,000.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.